Arterra Bioscience (ARBS) Q3 2025 TU earnings summary

Executive summary

• Revenue as of September 30, 2025, reached approximately €3.6 million, up 29% year-over-year from the same period in 2024.

• Sales of cosmetic raw materials contributed €3.1 million, a 34% increase compared to September 30, 2024.

• Service revenues totaled €520.7 thousand, up 7.4% year-over-year.

• Management expects to meet 2025 targets based on Q3 performance and current order book.

Financial highlights

• Total revenue for the first nine months of 2025: €3.58 million, up from €2.77 million in 2024.

• Cosmetic raw materials sales: €3.06 million in 2025 vs. €2.29 million in 2024.

• Service revenue: €520.7 thousand in 2025 vs. €484.9 thousand in 2024.

Outlook and guidance

• Management anticipates achieving full-year 2025 objectives, supported by strong Q3 results and order intake.

• Financial calendar for 2026 includes key dates for revenue and financial statement approvals.